Intuitive Surgical's Procedure Slowdown Overpowers Q2 Beat, Driving Shares to Oversold €299.60 Low
Published on 07/21/2026 at 03:32 | Redaktion boerse-global.de
Intuitive Surgical delivered a second-quarter earnings beat so clean that it would normally spark a rally: revenue surged 19% to $2.89 billion, earnings per share hit $2.80 against a consensus of $2.51, and operating margins widened to 23.7% from 21.8% a year earlier. Yet the stock cratered more than 23% over two trading sessions, sending the shares to a 52-week low of €299.60 on July 20 before a modest 2.43% bounce to €309.35. The culprit was not a miss, but a deceleration in the company's most closely watched metric—U.S. da Vinci procedure growth, which slowed to roughly 12%, the weakest pace since 2021 and well below the 13.2% the market had penciled in.
The slowdown stems from two factors detailed by management and analysts. Expiring subsidies tied to the Affordable Care Act have reduced the volume of certain procedures, while the rising popularity of GLP-1 weight-loss drugs is weighing on demand for bariatric surgeries. International procedure growth, by contrast, remained robust at 20%, and capital equipment sales showed no cracks: 468 new da Vinci systems were placed, a 19% increase driven by the next-generation da Vinci 5. The company also announced an expanded EndoWrist instrument usage program for the second half of 2027 that effectively lowers recurring costs for hospitals—a pricing concession whose margin impact Intuitive declined to quantify.
The market's punishment was unusually severe given the overall strength of the numbers, and the analyst community is now split on whether the sell-off represents an overreaction or the start of a structural repricing. More than a dozen banks cut their price targets. JPMorgan slashed its target to $450 from $550, while maintaining an Overweight rating. Bernstein lowered its target to $685 from $750 but simultaneously raised its 2027 EPS estimate to $12.71, signaling that the dip is seen as temporary. TD Cowen, Baird, and Wells Fargo also trimmed targets to between $487 and $520. The average analyst price target fell to roughly $504 from a prior $570, though one survey put the consensus at $523.46, reflecting the wide dispersion in valuations. Despite the cuts, 73% of 17 analysts still recommend Buy or Outperform.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
While the analyst community debates the trajectory, insiders have been quietly reducing their exposure. Director Amy Ladd sold 119 shares at $463.50 each, and EVP Gary Loeb offloaded 400 shares at $424.14. In total, twelve executives disposed of shares worth about $34 million through pre-arranged 10b5-1 trading plans, representing some 1.2% of their positions. Institutional investors are sending mixed signals: KBC Group trimmed its stake by 8.5% to 385,028 shares, while True North Advisors boosted its position by 18.1%, the Swiss National Bank added 5.9%, and Legacy Wealth Advisors increased by 25.4%. Overall, institutions still own roughly 84% of the company.
Technically, the stock is flashing oversold signals. The relative strength index sits at 33.6, a level that often precedes short-term bounces. From the 52-week high set in January, the shares are still down more than 40%, underscoring the scale of the valuation correction. The €299.60 low now serves as a critical support, with recovery attempts likely to face resistance around €380 to €390. The volume during the sell-off ran more than four times the daily average, suggesting a wave of forced and emotional selling that may have exhausted itself.
The debate now centers on whether the U.S. procedure growth deceleration is a temporary blip or the beginning of a structural shift. BMO Capital argued the slowdown linked to ACA subsidies is transitory and kept its $518 target with an Outperform rating. Zacks Equity Research, noting the 15% drop in four weeks, recommended buying the weakness. A Seeking Alpha contributor upgraded the stock to Buy after a 38% decline from an earlier Hold rating, arguing the correction had gone further than the fundamentals justify. With guidance pointing to the midpoint of the previously announced 13.5% to 15.5% procedure growth range for 2026, the market will need to see a reacceleration in coming quarters to restore confidence.
Ad
Intuitive Surgical Stock: New Analysis - 21 July
Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
